Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference
Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Eric Richman will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Eric Richman will participate in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This virtual event will enable investor access via webcast, available for 90 days post-event. Gain Therapeutics focuses on innovative drug discovery, particularly targeting allosteric binding sites related to neurodegenerative diseases and lysosomal storage disorders. Supported by notable foundations and programs, the company aims to provide new treatment options for challenging disorders linked to protein misfolding.
Details
News Market Reaction – GANX
The recorded move for GANX in the trading session of this news was -2.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman, will participate in the H.C. Wainwright Bioconnect Conference and invites investors to participate via webcast. Please see additional details below:
| H.C. Wainwright BioConnect Virtual Conference |
| Monday, January 10th - Wednesday, January 13th Registration Link A webcast will be available for 90 days on the Investor Relations section of the Gain Therapeutics website on January 10th at 7am ET or by using the following link: Webcast Link |
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
For more information, visit https://www.gaintherapeutics.com/
Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 617-430-7576
daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.